
    
      This is a 52-week multi-center study in subjects with type 2 diabetes mellitus who have
      inadequate glycemic control on an Î±-Glucosidase Inhibitor alone. Dosage may be increased
      during the treatment period if subjects fulfill increasing criteria and the investigators
      adjudicate that no impact for subjects safety.
    
  